Table 1. Treatment Groups for HCT116 +/+ and HCT116 −/− Tumor–Bearing Mice.

Group	Injection
1	Intraperitoneal: 150 μL of saline
2	Intraperitoneal: cisplatin (5 mg/kg) in 150 μL of saline
3	Intravenous: 22.2 MBq (600 μCi) of 64Cu-DOTA-cetuximab in 150 μL of saline
4	Intraperitoneal: cisplatin (5 mg/kg) in 150 μL of saline, followed by intravenous injection of 22.2 MBq (600 μCi) of 64Cu-DOTA-cetuximab in 150 μL of saline after 24 h
5	Intravenous: 50 μg of cetuximab in 150 μL of saline
6	Intraperitoneal: cisplatin (5 mg/kg) in 150 μL of saline, followed by intravenous injection of 50 μg of cetuximab in 150 μL of saline after 24 h
7	Intravenous: 22.2 MBq (600 μCi) of 64Cu-IgG in 150 μL of saline

Mice received 2 treatments 1 wk apart for each group.